Shots:
The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.
Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
Shots:
The US FDA has approved Flyrcado injection as a PET MPI agent to diagnose CAD, with its launch planned in early 2025
The effectiveness of Flyrcado was assessed under the P-III (AURORA) study in comparison with both invasive coronary angiography as a standard and SPECT MPI to identify CAD
In addition, GE HealthCare secured…

